TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7813261

Group type: EXPERIMENTAL
Intervention: Clinical radiologists and study radiologists measuring mediastinal lymph node size in CT scans.
Number of subjects: 60
Study: 1950483

Group type: EXPERIMENTAL
Intervention: Diclofenac (NSAID)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7274202

Group type: EXPERIMENTAL
Intervention: Zinc ammonium sulfate aerosol at a nominal concentration of 20 μg/m3
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control: Sodium chloride aerosol at a nominal concentration of 300 μg/m3
Number of subjects: 40
Study: 31186401

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo or no compound
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30593763

Group type: EXPERIMENTAL
Intervention: Compressed fixation combined with vacuum‐assisted closure
Number of subjects: 53

Group type: COMPARATOR
Intervention: Only reimplanted and sewn
Number of subjects: 53
Study: 26723272

Group type: EXPERIMENTAL
Intervention: Specialized outpatient physiotherapy programme (Bleton technique)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard physiotherapy advice for neck problems
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups (Specialized and Standard physiotherapy)
Number of subjects: 110
Study: 24496083

Group type: EXPERIMENTAL
Intervention: Self-reported prevalent diabetes
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Self-reported incident diabetes
Number of subjects: 732

Group type: COMPARATOR
Intervention: No self-reported diabetes
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Claims algorithm in fee-for-service Medicare participants
Number of subjects: 732
Study: 22695310

Group type: EXPERIMENTAL
Intervention: 400 mg vaginal natural progesterone
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 20064284

Group type: EXPERIMENTAL
Intervention: UMF 20+ honey (20 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Multiflora honey (20 g)
Number of subjects: 20
Study: 17378904

Group type: EXPERIMENTAL
Intervention: Iberogast (1.1 mL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (1.1 mL)
Number of subjects: 29
Study: 16344226

Group type: EXPERIMENTAL
Intervention: Dobutamine myocardial SPECT using technetium 99m sestamibi
Number of subjects: 50
Study: 12439764

Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (c.c.HRT) with 1 mg estradiol plus 0.5 mg norethisterone acetate (NETA)
Number of subjects: 3917
Study: 10450296

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Combination diet
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study: 7547823

Group type: EXPERIMENTAL
Intervention: 300 mg elemental Calcium
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 2201403

Group type: EXPERIMENTAL
Intervention: ABO-mismatched platelets (MMG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: ABO-matched platelets (OG)
Number of subjects: 43
Study: 6996139

Group type: EXPERIMENTAL
Intervention: Intravenous injection of diazepam plus local anaesthetic spray
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia (methohexital plus succinylcholine)
Number of subjects: 50
Study: 30870159

Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg/kg bolus followed by continuous infusion (48 μg · kg · min for the first hour, 24 μg · kg · min for the second hour, and 10 μg · kg · min for the next 46 hours)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo (saline with identical volume and rate changes)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study: 28877558

Group type: EXPERIMENTAL
Intervention: Higher social status (leaders)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lower social status (followers)
Number of subjects: 60
Study: 25795741

Group type: EXPERIMENTAL
Intervention: Physician care (additional intervention by a physician arriving by helicopter)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Standard ground paramedic treatment
Number of subjects: 375
Study: 24012890

Group type: EXPERIMENTAL
Intervention: 3-year healthy lifestyle intervention
Number of subjects: 600

Group type: COMPARATOR
Intervention: 3-year school readiness program
Number of subjects: 600
Study: 21429816

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 23
Study: 19549748

Group type: EXPERIMENTAL
Intervention: GH reintroduction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17827951

Group type: EXPERIMENTAL
Intervention: rifaximin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: mesalazine
Number of subjects: 58
Study: 15090392

Group type: EXPERIMENTAL
Intervention: Active low-energy extracorporeal shock wave treatment given weekly for 3 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo extracorporeal shock wave treatment (sham)
Number of subjects: 78
Study: 16050432

Group type: EXPERIMENTAL
Intervention: Morning bright light exposure (> or = 2500 lux in gaze direction) for 1 hour (09:30-10:30) Monday through Friday for 10 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual indoor light (150-200 lux)
Number of subjects: 46
Study: 10325829

Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 9

Group type: COMPARATOR
Intervention: 20% nitrogen gas mixture
Number of subjects: 9
Study: 9772598

Group type: EXPERIMENTAL
Intervention: Lappaconitine compound (12 mg lappaconitine and 22.5 mg bupivacaine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Morphine (2 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lappaconitine (12 mg) and bupivacaine (22.5 mg)
Number of subjects: 120
Study: 1926895

Group type: EXPERIMENTAL
Intervention: Peer-led education
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Teacher-led education
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25
Study: 6416059

Group type: EXPERIMENTAL
Intervention: Paregoric
Number of subjects: 31

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 31
Study: 30723735

Group type: EXPERIMENTAL
Intervention: Combination of nutraceuticals containing 5 mg monacolin K, 200 mg Citrus bergamia, 400 mg Omega‐3, and 10 mcg trivalent chromium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of nutraceuticals containing 3 mg monacolin K, 200 mg red yeast rice, 500 mg Berberine, 0.5 mg Astaxanthin, 200 mcg folic acid, 2 mg Coenzyme Q10, and 10 mg Policosanol
Number of subjects: 50
Study: 28963804

Group type: EXPERIMENTAL
Intervention: Synchronous telepractice care
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 82
Study: 26281163

Group type: EXPERIMENTAL
Intervention: De-Nol (bismuth subcitrate)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Novobismol
Number of subjects: 40
Study: 25294299

Group type: EXPERIMENTAL
Intervention: Beetroot juice concentrate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Blackcurrant juice (control)
Number of subjects: 24
Study: 22801191

Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA injections (300 IU)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Suburothelial onabotulinumtoxinA injections (300 IU)
Number of subjects: 32
Study: 19241108

Group type: EXPERIMENTAL
Intervention: Aspirin (low dose)
Number of subjects: 1598

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1598

Group type: COMPARATOR
Intervention: No tablets
Number of subjects: 1598
Study: 17428299

Group type: EXPERIMENTAL
Intervention: BoNTA 225 U
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: BoNTA 150 U
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: BoNTA 75 U
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study: 14989807

Group type: EXPERIMENTAL
Intervention: 1-day mifepristone-misoprostol interval
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2-day mifepristone-misoprostol interval
Number of subjects: 200
Study: 12536709

Group type: EXPERIMENTAL
Intervention: Radiofrequency
Number of subjects: 310

Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 310
Study: 9849032

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis antibodies
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: N. gonorrhoeae antibodies
Number of subjects: 121
Study: 9156955

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg, once daily)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Nifedipine SR (20 mg, twice daily)
Number of subjects: 234
Study: 29354933

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with Chinese herbal formula and letrozole
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chinese herbal formula and letrozole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 120
Study: 28552655

Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic plexus ablation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Laparoscopic uterine artery occlusion and partial adenomyomectomy (control)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Operative time
Number of subjects: 102
Study: 26283529

Group type: EXPERIMENTAL
Intervention: Enhanced nutrition health care standards (intervention group)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 960
Study: 23043154

Group type: EXPERIMENTAL
Intervention: Continence promotion interventions (3 experimental interventions)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 667
Study: 21401409

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Traditional surgical technique
Number of subjects: 63
Study: 18665761

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) 20 min a day with a 5‐mW soft laser for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Betahistine 16 mg twice a day for 6 months
Number of subjects: 20
Study: 16494539

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open splenectomy
Number of subjects: 28
Study: 14609899

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) for 30 minutes before and during heel-lancing procedure
Number of subjects: 74

Group type: COMPARATOR
Intervention: Prone position in the isolette (control condition)
Number of subjects: 74
Study: 10833331

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 244

Group type: COMPARATOR
Intervention: CBS gene polymorphisms 699C ‐‐> T and 1080T ‐‐> C
Number of subjects: 244
Study: 9438012

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 8441234

Group type: EXPERIMENTAL
Intervention: rhIGF-I, 60 micrograms/kg, subcutaneous injections, administered at 0800, 1400, and 2000 hours for 5.5 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (non-volume expanded and saline loaded subjects without rhIGF-I)
Number of subjects: 8
Study: 2428593

Group type: EXPERIMENTAL
Intervention: WORD task
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CASE/WORD task
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Degraded stimuli
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: WORD and CASE tasks
Number of subjects: 10
Study: 28870129

Group type: EXPERIMENTAL
Intervention: Volar plating (surgical treatment)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conservative treatment (casting)
Number of subjects: 97
Study: 26962133

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3445
Study: 25741871

Group type: EXPERIMENTAL
Intervention: PictureRx illustrated medication list
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (written list of medications in preferred language, with indication but no images)
Number of subjects: 200
Study: 22237419

Group type: EXPERIMENTAL
Intervention: sifilcon A penetrated hydrogel lenses (Dk/t ± 117) worn on a daily basis for 9 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (11 non-lens wearers)
Number of subjects: 21
Study: 20837741

Group type: EXPERIMENTAL
Intervention: Mandibular two-implant overdenture (OD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Complete dentures (CD)
Number of subjects: 20
Study: 18498682

Group type: EXPERIMENTAL
Intervention: Chunghyul-dan 600 mg a day
Number of subjects: 148

Group type: COMPARATOR
Intervention: Antiplatelet agents
Number of subjects: 148
Study: 16279156

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 3
Study: 11952269

Group type: EXPERIMENTAL
Intervention: Helical pitch 1.0
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Helical pitch 1.3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Helical pitch 1.5
Number of subjects: 60
Study: 10081854

Group type: EXPERIMENTAL
Intervention: Transurethral resection plus 100 mg. epirubicin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transurethral resection plus 50 million units interferon-alpha2b
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transurethral resection only
Number of subjects: 200
Study: 7498868

Group type: EXPERIMENTAL
Intervention: 100 to 120 mg of hypericum extract bid
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: hypericum extract
Number of subjects: 97
Study: 2206813

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (intramuscular)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Amoxycillin (oral)
Number of subjects: 466
Study: 7002569

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day by mouth, in three divided doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (weight‐ and disease‐matched)
Number of subjects: 20
Study: 31066232

Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfonate (STS) 80 mg qd for 7 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfonate (STS)
Number of subjects: 101
Study: 30214156

Group type: EXPERIMENTAL
Intervention: Asenapine 1-10 mg twice daily for up to 12 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asenapine 2.5-10 mg twice daily for up to 8 weeks
Number of subjects: 0
Study: 27810972

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) - 2 doses (1 g/kg/dose)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 308
Study: 24630936

Group type: EXPERIMENTAL
Intervention: Implicit affective associations with fruits
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Explicit measures of affective associations
Number of subjects: 107
Study: 22290978

Group type: EXPERIMENTAL
Intervention: Asunaprevir (200 to 600 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20814282

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus mepivacaine
Number of subjects: 45
Study: 17221340

Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 43
Study: 16250190

Group type: EXPERIMENTAL
Intervention: Augmented exercise therapy time as Arm BASIS training (n=20)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Augmented exercise therapy time as Bobath therapy (n=20)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No augmented exercise therapy time (n=20)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Augmented exercise therapy time as Arm BASIS training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Augmented exercise therapy time as Bobath therapy
Number of subjects: 62
Study: 11872999

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + lamivudine (3TC) + indinavir (IDV)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + lamivudine (3TC)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) + indinavir (IDV)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Triple-drug regimen (ZDV + 3TC + IDV)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Less intensive regimens (ZDV + 3TC or ZDV + IDV)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Reinitiating either the original triple-drug regimen or a new combination of nucleoside analogue reverse transcriptase inhibitors and protease inhibitors
Number of subjects: 279
Study: 10467900

Group type: EXPERIMENTAL
Intervention: 3 mg of haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 11 mg of midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg of scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7834398

Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg rCD4‐IgG twice per week and 600 mg ZDV per day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1,000 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1,000 micrograms/kg rCD4‐IgG twice per week and 600 mg ZDV per day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 3,000 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 41
Study: 1964662

Group type: EXPERIMENTAL
Intervention: CY 216 (0.3 ml subcutaneous injections equivalent to 7,500 anti-Xa units)
Number of subjects: 4498

Group type: COMPARATOR
Intervention: Placebo (0.3 ml saline solution)
Number of subjects: 4498
Study: 6155131

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 120 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 180 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 15 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 30 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31958446

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg orally on day 1 and then 80 mg orally on days 2 to 7 with physician's choice of antitussive
Number of subjects: 128

Group type: COMPARATOR
Intervention: Physician's choice of antitussive alone
Number of subjects: 128
Study: 29484635

Group type: EXPERIMENTAL
Intervention: Dipeptidyl Peptidase 1 Inhibitor AZD7986
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26465781

Group type: EXPERIMENTAL
Intervention: OCTREE (intraportal chemotherapy plus mFOLFOX6)
Number of subjects: 237

Group type: COMPARATOR
Intervention: mFOLFOX6 (standard adjuvant chemotherapy)
Number of subjects: 237
Study: 23743626

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2

Group type: COMPARATOR
Intervention: Distraction condition
Number of subjects: 2

Group type: COMPARATOR
Intervention: Accuracy motivation condition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Facial width-to-height ratio (FWHR)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Attractiveness
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Masculinity
Number of subjects: 2
Study: 22533501

Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS) practice
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no HPS practice)
Number of subjects: 85
Study: 20557366

Group type: EXPERIMENTAL
Intervention: 14-day quadruple therapy (Omeprazole 20 mg, Amoxicillin 1.0 g, Clarithromycin 500 mg, Bismuth Potassium Citrate 220 mg, twice a day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 7-day quadruple therapy (Omeprazole 20 mg, Amoxicillin 1.0 g, Clarithromycin 500 mg, Bismuth Potassium Citrate 220 mg, twice a day)
Number of subjects: 160
Study: 18447631

Group type: EXPERIMENTAL
Intervention: GoChi (120 mL/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 34
Study: 16414904

Group type: EXPERIMENTAL
Intervention: Non thermal dual wavelength light source (405-420 nm and 850-900 nm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glycolic peeling and daily appliance of vitamin C
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated by the light source
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated by the light source or treated by the light source on one side only
Number of subjects: 60
Study: 12878618

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.08 micro g kg(‐1) min(‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study: 10762640

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR (460 mg/m2/day, daily, for two years)
Number of subjects: 485

Group type: COMPARATOR
Intervention: 5‐FU (115 mg/m2/day, daily, for two years)
Number of subjects: 485
Study: 9467249

Group type: EXPERIMENTAL
Intervention: HBA1 concentration
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose concentration
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Measurement of HBA1
Number of subjects: 37
Study: 1634913

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 IV on day 1 and 5‐FU 1,000 mg/m2 per day for a 96‐hour continuous infusion repeated every 21 days
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 IV on day 1 and 5‐FU 1,000 mg/m2 per day for a 96‐hour continuous infusion repeated every 28 days
Number of subjects: 277

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 40 mg/m2 IV given weekly
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Cisplatin plus 5‐FU
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Carboplatin plus 5‐FU
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Treatment assigned
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Performance status
Number of subjects: 277
Study: 6702613

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11